Gout therapeutics encompass medications designed to exert therapeutic effects in addressing the medical condition known as gout, or inflammatory arthritis, characterized by pain and swelling in joints. These therapeutics aim to treat and alleviate pain, swelling, and tenderness associated with gout.
The primary categories of gout therapeutics include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and diuretics. Non-steroidal anti-inflammatory drugs (NSAIDs) are medications employed to reduce inflammation, relieve pain, and lower elevated body temperatures. Treatment options encompass xanthine oxidase inhibitors and uricosuria medications tailored for various disease conditions, including both acute and chronic cases. These therapeutics find application across various end-users, including hospitals, specialty clinics, and others.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The gout therapeutics market research report is one of a series of new reports from The Business Research Company that provides gout therapeutics market statistics, including gout therapeutics industry global market size, regional shares, competitors with a gout therapeutics market share, detailed gout therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the gout therapeutics industry. This gout therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The gout therapeutics market size has grown rapidly in recent years. It will grow from $2.88 billion in 2024 to $3.22 billion in 2025 at a compound annual growth rate (CAGR) of 11.9%. The growth in the historic period can be attributed to increased prevalence of gout, changed lifestyle and dietary patterns, high blood pressure and diabetes prevalence, development of xanthine oxidase inhibitors, patient education initiatives.
The gout therapeutics market size is expected to see rapid growth in the next few years. It will grow to $5 billion in 2029 at a compound annual growth rate (CAGR) of 11.7%. The growth in the forecast period can be attributed to rising healthcare expenditure, advancements in drug delivery systems, emerging novel therapies, government initiatives for chronic disease management, patient advocacy and support groups. Major trends in the forecast period include innovative drug development, novel drug approvals, personalized medicine approaches, telehealth services for gout management, research in urate-lowering therapies.
The forecast of 11.7% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. by increasing the cost of febuxostat and pegloticase sourced from Japan and Belgium, thereby reducing medication adherence for chronic gout patients and elevating rheumatology department expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The increasing prevalence of gout is anticipated to drive the expansion of the gout therapeutics market in the future. Gout is an inflammatory arthritis condition characterized by pain and swelling in the joints, and gout therapeutics aim to treat and alleviate this pain, swelling, and tenderness. Consequently, the rising incidence of gout is expected to enhance sales in the gout therapeutics market. For example, in June 2024, the Australian Institute of Health and Welfare, a government agency based in Australia, reported that gout was recorded as an underlying cause in 573 deaths in the country in 2022, representing 2.2 deaths per 100,000 people. Therefore, the growing incidence of gout is a significant factor driving the growth of the gout therapeutics market.
The growing prevalence of obesity is anticipated to fuel the expansion of the gout therapeutics market in the years to come. Obesity, characterized by an abnormal accumulation of body fat, is considered a major risk factor for the onset and exacerbation of gout. Obesity can intensify the frequency and severity of gout attacks, posing challenges in their management. According to the World Health Organization's March 2022 report, over 1 billion individuals globally, including 340 million adolescents, 39 million children, and 650 million adults, are affected by obesity. The prevalence of obesity continues to rise, with WHO projections indicating that by 2025, 167 million adults and children will face health consequences due to being overweight or obese. Therefore, the increasing prevalence of obesity stands as a driving force for the gout therapeutics market.
Product innovation is a prominent trend gaining traction in the gout therapeutics market, with major companies actively engaged in developing innovative treatments to maintain their competitive edge. An example of such innovation is seen in the August 2022 launch of SYNB2081 by Synlogic Inc., a US-based pharmaceutical company. SYNB2081, a synthetic biotic, represents a novel drug candidate designed for gout treatment, specifically aimed at lowering uric acid levels. This development is the outcome of a collaborative research effort between Synlogic and Ginkgo, a US-based biotech company.
Major companies in the gout therapeutics market are focusing on the development of innovative products, such as corticotropin. Corticotropin, also known as adrenocorticotropic hormone (ACTH), is a peptide hormone secreted by the anterior pituitary gland in response to low cortisol levels in the blood. An illustration of this is seen in the January 2022 launch of Purified Cortrophin Gel (Repository Corticotropin Injection USP) 80 U/mL by ANI Pharmaceuticals, Inc., a US-based pharmaceutical company. This gel, an adrenocorticotropic hormone (ACTH), is marketed by ANI's newly established rare illness business unit and is used in the treatment of chronic autoimmune conditions such as acute exacerbations of multiple sclerosis (MS) and gouty arthritis (GA), as well as excess urine protein due to nephrotic syndrome.
In December 2022, Innovent Biologics, a China-based biopharmaceutical company, and LG Chem Life Sciences, a US-based pharmaceutical company, forged a strategic collaboration and license agreement for LG Chem's Tigulixostat, intended for the chronic management of hyperuricemia in patients with gout disease. This partnership grants Innovent exclusive rights to develop and commercialize Tigulixostat in China for $95.5 million, encompassing a $10 million upfront payment. LG Chem stands to receive milestones and tiered royalties based on net product sales in China. Tigulixostat, a novel xanthine oxidase inhibitor, targets the reduction of uric acid in purine metabolism, showcasing a therapeutic intervention for gout.
Major companies operating in the gout therapeutics market include Sanofi-Aventis, AstraZeneca plc, LG Chem Ltd., GlaxoSmithKline Plc, Takeda Pharmaceuticals Co. Ltd., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Sandoz, Eisai Co. Ltd., Horizon Pharma Plc, Jiangsu HengRui Medicine Co. Ltd., Hikma Pharmaceuticals plc, Swedish Orphan Biovitrum AB, JW Pharmaceutical Corp, Lannett Company Inc, BioCryst Pharmaceuticals Inc., Selecta Biosciences Inc., Rigel Pharmaceuticals Inc., CymaBay Therapeutics Inc., GeneScience Pharmaceuticals Co. Ltd., Shanton Pharma
North America was the largest region in the gout therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gout therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the gout therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The gout therapeutics market consists of the sales of allopurinol, benzbromarone, febuxostat, probenecid, and pegloticase drugs. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Gout Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on gout therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for gout therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The gout therapeutics market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Type: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs); Corticosteroid; Diuretics
- 2) By Treatment: Xanthine Oxidase Inhibitor; Uricosuria Medication
- 3) By Disease Condition: Acute; Chronic
- 4) By End-Users: Hospitals; Specialty Clinics; Other End Users
- Subsegments:
- 1) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Traditional NSAIDs; Selective COX-2 Inhibitors
- 2) By Corticosteroid: Oral Corticosteroids; Injectable Corticosteroids
- 3) By Diuretics: Thiazide Diuretics; Loop Diuretics
- Companies Mentioned: Sanofi-Aventis; AstraZeneca plc; LG Chem Ltd.; GlaxoSmithKline Plc; Takeda Pharmaceuticals Co. Ltd.; Boehringer Ingelheim International GmbH; Regeneron Pharmaceuticals Inc.; Astellas Pharma Inc.; Sandoz; Eisai Co. Ltd.; Horizon Pharma Plc; Jiangsu HengRui Medicine Co. Ltd.; Hikma Pharmaceuticals plc; Swedish Orphan Biovitrum AB; JW Pharmaceutical Corp; Lannett Company Inc; BioCryst Pharmaceuticals Inc.; Selecta Biosciences Inc.; Rigel Pharmaceuticals Inc.; CymaBay Therapeutics Inc.; GeneScience Pharmaceuticals Co. Ltd.; Shanton Pharma
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time Series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Gout Therapeutics Market Characteristics
3. Gout Therapeutics Market Trends And Strategies
4. Gout Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
- 4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Gout Therapeutics Growth Analysis And Strategic Analysis Framework
- 5.1. Global Gout Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Gout Therapeutics Market Growth Rate Analysis
- 5.4. Global Gout Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Gout Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Gout Therapeutics Total Addressable Market (TAM)
6. Gout Therapeutics Market Segmentation
- 6.1. Global Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- Corticosteroid
- Diuretics
- 6.2. Global Gout Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Xanthine Oxidase Inhibitor
- Uricosuria Medication
- 6.3. Global Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Acute
- Chronic
- 6.4. Global Gout Therapeutics Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Specialty Clinics
- Other End-Users
- 6.5. Global Gout Therapeutics Market, Sub-Segmentation Of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Traditional NSAIDs
- Selective COX-2 Inhibitors
- 6.6. Global Gout Therapeutics Market, Sub-Segmentation Of Corticosteroid, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oral Corticosteroids
- Injectable Corticosteroids
- 6.7. Global Gout Therapeutics Market, Sub-Segmentation Of Diuretics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Thiazide Diuretics
- Loop Diuretics
7. Gout Therapeutics Market Regional And Country Analysis
- 7.1. Global Gout Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Gout Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Gout Therapeutics Market
- 8.1. Asia-Pacific Gout Therapeutics Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Gout Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Gout Therapeutics Market
- 9.1. China Gout Therapeutics Market Overview
- 9.2. China Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Gout Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Gout Therapeutics Market
- 10.1. India Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Gout Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Gout Therapeutics Market
- 11.1. Japan Gout Therapeutics Market Overview
- 11.2. Japan Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Gout Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Gout Therapeutics Market
- 12.1. Australia Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Gout Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Gout Therapeutics Market
- 13.1. Indonesia Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Gout Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Gout Therapeutics Market
- 14.1. South Korea Gout Therapeutics Market Overview
- 14.2. South Korea Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Gout Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Gout Therapeutics Market
- 15.1. Western Europe Gout Therapeutics Market Overview
- 15.2. Western Europe Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Gout Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Gout Therapeutics Market
- 16.1. UK Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Gout Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Gout Therapeutics Market
- 17.1. Germany Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Gout Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Gout Therapeutics Market
- 18.1. France Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Gout Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Gout Therapeutics Market
- 19.1. Italy Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Gout Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Gout Therapeutics Market
- 20.1. Spain Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Gout Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Gout Therapeutics Market
- 21.1. Eastern Europe Gout Therapeutics Market Overview
- 21.2. Eastern Europe Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Gout Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Gout Therapeutics Market
- 22.1. Russia Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Gout Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Gout Therapeutics Market
- 23.1. North America Gout Therapeutics Market Overview
- 23.2. North America Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Gout Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Gout Therapeutics Market
- 24.1. USA Gout Therapeutics Market Overview
- 24.2. USA Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Gout Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Gout Therapeutics Market
- 25.1. Canada Gout Therapeutics Market Overview
- 25.2. Canada Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Gout Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Gout Therapeutics Market
- 26.1. South America Gout Therapeutics Market Overview
- 26.2. South America Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Gout Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Gout Therapeutics Market
- 27.1. Brazil Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Gout Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Gout Therapeutics Market
- 28.1. Middle East Gout Therapeutics Market Overview
- 28.2. Middle East Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Gout Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Gout Therapeutics Market
- 29.1. Africa Gout Therapeutics Market Overview
- 29.2. Africa Gout Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Gout Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Gout Therapeutics Market, Segmentation By Disease Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Gout Therapeutics Market Competitive Landscape And Company Profiles
- 30.1. Gout Therapeutics Market Competitive Landscape
- 30.2. Gout Therapeutics Market Company Profiles
- 30.2.1. Sanofi-Aventis Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. LG Chem Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. GlaxoSmithKline Plc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Takeda Pharmaceuticals Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
31. Gout Therapeutics Market Other Major And Innovative Companies
- 31.1. Boehringer Ingelheim International GmbH
- 31.2. Regeneron Pharmaceuticals Inc.
- 31.3. Astellas Pharma Inc.
- 31.4. Sandoz
- 31.5. Eisai Co. Ltd.
- 31.6. Horizon Pharma Plc
- 31.7. Jiangsu HengRui Medicine Co. Ltd.
- 31.8. Hikma Pharmaceuticals plc
- 31.9. Swedish Orphan Biovitrum AB
- 31.10. JW Pharmaceutical Corp
- 31.11. Lannett Company Inc
- 31.12. BioCryst Pharmaceuticals Inc.
- 31.13. Selecta Biosciences Inc.
- 31.14. Rigel Pharmaceuticals Inc.
- 31.15. CymaBay Therapeutics Inc.
32. Global Gout Therapeutics Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Gout Therapeutics Market
34. Recent Developments In The Gout Therapeutics Market
35. Gout Therapeutics Market High Potential Countries, Segments and Strategies
- 35.1 Gout Therapeutics Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Gout Therapeutics Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Gout Therapeutics Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
